People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BALX Holdings, LLC | — | Biotechnology | Series A | $9.0M | $72.3M | 2016 |
Max J. Osofsky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Max J. Osofsky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James A. Datin | 1 | 6 |
| Todd A. Lynch | 1 | 1 |
| Michael J. Lehmann | 1 | 1 |
| David A. Belluck | 1 | 1 |
| Mike A. Magliochetti | 1 | 1 |
| Jeremy A. Goldberg | 1 | 1 |
| Craig A. Stern | 1 | 1 |
| Philip J. Borden | 1 | 1 |
| Kurt J. Brykman | 1 | 1 |
| Caroline A. Popper | 1 | 1 |
| Afshin A. Safavi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.